Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment ... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.52 | 11.6331096197 | 4.47 | 6.44 | 4.3557 | 1608307 | 5.60686462 | CS |
| 4 | 0.511 | 11.4087966064 | 4.479 | 6.44 | 4.3557 | 761790 | 5.3723641 | CS |
| 12 | 2.1 | 72.6643598616 | 2.89 | 6.44 | 2.66 | 1621714 | 4.14843328 | CS |
| 26 | 1.07 | 27.2959183673 | 3.92 | 6.44 | 2.39 | 968292 | 3.94424272 | CS |
| 52 | -1 | -16.694490818 | 5.99 | 20.71 | 2.39 | 1033901 | 7.03235194 | CS |
| 156 | -10.51 | -67.8064516129 | 15.5 | 20.71 | 2.13 | 761857 | 7.1490568 | CS |
| 260 | -10.51 | -67.8064516129 | 15.5 | 20.71 | 2.13 | 761857 | 7.1490568 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
